Background: Low-grade nasopharyngeal papillary adenocarcinoma (LGNPPA) is distinctly rare. We report a patient with a uniquely biphasic LGNPPA; additionally, we review similar tumors reported in the literature.
Case Presentation: A 56-year-old man presented with an asymptomatic pedunculated tumor in the vault of the nasopharynx, at the junction of the nasal septum and the roof, which was discovered during screening for laryngeal cancer. To obtain a definitive diagnosis, the patient underwent endoscopic endonasal surgery under general anesthesia. Immunohistochemical analysis of the tumor revealed it to be an LGNPPA with a prominent spindle cell component.
Conclusion: To our knowledge, this is the fourth reported LGNPPA exhibiting a spindle cell component and the second with a prominent pathological condition. The prognosis of LGNPPA is usually excellent. Therefore, it is important for clinicians to scrutinize the lesion's pathology to avoid unnecessary, disfiguring surgery.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172832 | PMC |
| http://dx.doi.org/10.1186/s12907-018-0076-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Low-grade Nasopharyngeal Papillary Adenocarcinoma: A Clinicopathologic Series of 35 Cases.
Am J Surg Pathol
January 2025
Department of Pathology, Eye & ENT Hospital, Fudan University.
Article Synopsis
- Low-grade nasopharyngeal papillary adenocarcinoma (LGNPPA) is a rare cancer affecting the nasopharynx, with a study involving 35 patients revealing common symptoms like nasal obstruction and rhinorrhea, primarily in individuals aged 11 to 71.
- Most tumors were T1N0M0 stage and exhibited irregular papillary structures, with various histopathological features, such as squamous differentiation in some cases and a significant spindle cell component in many.
- Treatment typically involves endoscopic surgical resection, and follow-up showed no recurrence or metastasis in patients, supporting the idea that LGNPPA may be better categorized as a primary papillary epithelial tumor due to its slow-growing nature.
Description and Characterization of Different Types of Lymphoma in Cats in Hong Kong.
Animals (Basel)
May 2024
Department of Veterinary Clinical Sciences, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong.
This study aimed to characterize and describe the different lymphoma types and anatomical forms in cats in Hong Kong. The clinical and histopathological data of cats diagnosed with lymphoma by cytology and/or histopathology were collected from a large diagnostic laboratory in Hong Kong. In total, 444 cats were diagnosed with lymphoma over four years (2019-2022).
View Article and Find Full Text PDFCase report: Successful management of primary hyalinizing clear cell carcinoma in nasopharynx: a report of 2 cases and system analysis.
Front Oncol
May 2024
Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hyalinizing clear cell carcinomas (HCCCs) are infrequent, malignant tumors characterized by their low-grade nature. They typically originate from minor salivary glands. However, these tumors can potentially emerge in any location with minor salivary glands, including the nasopharynx.
View Article and Find Full Text PDFPolymorphous adenocarcinoma of minor salivary gland: Case presentation and literature review.
Int J Surg Case Rep
June 2024
Otolaryngology, Head & Neck Surgery and Microvascular Reconstructive Surgery, Saudi Arabia; Department of Otolaryngology-Head and Neck Surgery, Security Forces Hospital, Riyadh, Saudi Arabia.
Introduction And Importance: Polymorphous low-grade adenocarcinoma (PLGA) is a rare neoplasm arising from minor salivary glands, representing approximately 3 % of head and neck tumors. The clinical presentation of PLGA is defined as a painless, slow-growing tumor, mostly occurring in the palate. We report a case of PLGA with a rare presentation.
View Article and Find Full Text PDFNew hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
Front Immunol
April 2024
Surgical Oncology Clinic, Institute of Oncology, Poznan University of Medical Sciences, Poznan, Poland.
Oncolytic virus (OV) therapy has emerged as a promising frontier in cancer treatment, especially for solid tumours. While immunotherapies like immune checkpoint inhibitors and CAR-T cells have demonstrated impressive results, their limitations in inducing complete tumour regression have spurred researchers to explore new approaches targeting tumours resistant to current immunotherapies. OVs, both natural and genetically engineered, selectively replicate within cancer cells, inducing their lysis while sparing normal tissues.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!